Neuromodulation Market

Report Code BT 3571
Published in Jan, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson's Disease, Depression, Gastroparesis), and Region - Global Forecast to 2028

Overview

The global Neuromodulation market in terms of revenue was estimated to be worth $6.2 Billion in 2023 and is poised to reach $11.0 Billion by 2028, growing at a CAGR of 12.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by the prevalence of neurological disorders and nerve injuries, increasing focus on the development of advanced neuromodulation and neurostimulation technologies, government support for research on neurological disorders, growing geriatric population and subsequent increase in the prevalence of neurological disorders, availability of reimbursement of neuromodulation devices, collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices.

Attractive Opportunities in the Neuromodulation Market

ASIA PACIFIC

Growth in the Asia Pacific market can be attributed to the growing geriatric population, and the rising prevalence of neurological disorders.

Growth of the overall market is largely driven by the increasing incidence of neurological disorders, increasing research in the field of neurology, and rising awareness regarding neuromodulation devices

Product launches are the key growth strategies adopted by market players.

The North American Market is projected to hold the largest market share

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

Global Neuromodulation Market Dynamics

DRIVER: Increasing focus on the development of advanced neuromodulation and neurostimulation technologies

In recent years, many of the companies and researchers have focused on developing advanced neuromodulation and neurostimulation devices for nerve repair & regeneration.In July 2023, Boston Scientific received the US FDA approval for the Vercise Neural Navigator 5 Software.In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson’s disease and those undergoing deep brain stimulation (DBS).In May 2021, researchers from the University of Oxford, the University of California San Francisco (UCSF), the Mayo Clinic, and Brown University are entered into collaboration to form a multi-partner “OpenMind” consortium to develop an open-source technology platform for next-generation neurostimulation devices. The device would perform brain stimulation and sense, record, and stream activities in the brain.Such strategic collaborations among market players are expected to lead to the development of advanced technologies related to neuromodulation and neurostimulation devices, thus driving the growth of the overall market.

RESTRAINT: Preference for drug therapies over neuromodulation products

Most of the patients are prefer drug therapies over neuromodulation for treating neurological disorders. This is due to limited patient awareness about the availability of alternative surgical treatments which can be used neuromodulation devices. The lack of awareness is also evident in surgeons in some countries. For instance, overactive bladder (OAB) syndrome remains untreated in many individuals across the globe Thus, the lack of awareness about the benefits of using neuromodulation devices to treat neurological diseases is expected to restrain the growth of this market during the forecast period.

 

OPPORTUNITY: Large population and increasing healthcare expenditure in emerging countries

Emerging countries like India, China, and Brazil are expected to offer potential growth opportunities for market players during the forecast period. The population base, especially in China and India, is expected to attract a larger number of companies in this market. This can be supported by the rising incidence of neurological diseases like Parkinson’s, Alzheimer’s, and epilepsy. According to estimates published in PubMed, by 2030, 4.94 million people in China will have Parkinson’s, accounting for nearly half of all patients globally.

CHALLENGE: Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices

Stringent regulations and time-consuming approval processes for neuromodulation and neurostimulation devices are considered a major challenge for companies operating in this market. The regulatory approval process differs for different medical devices in most countries based on their risk profile. For instance, medical devices are categorized into three classes in the US based on their risk profile—Class I, Class II, and Class III. Depending on the application, neuromodulation and neurostimulation devices fall under Class II or Class III medical devices and require premarket notification via the 510(k) process for their approval and launch in the US market. For instance, spinal cord stimulators fall under Class II for applications such as managing chronic and intractable pain and Class III for applications such as pain relief. Players focusing on launching their neuromodulation products in the US face major challenges as the number of premarket approvals granted over the years has reduced. The time required for FDA internal review and abbreviated 510(k) approvals has recently increased.

Global Neuromodulation Market Ecosystem Analysis

In 2022, internal accounted for the largest share in the neuromodulation industry, by type. The neuromodulation market is segmented into internal and external neuromodulation. In 2022, Internal neuromodulation accounted for the largest share of the market. The major market can be attributed to the benefits of internal neuromodulation procedures, such as reduced post-surgical complications, shorter hospitalizations, and improved quality of life, which are expected to contribute to the significant share of the type segment.

 

In 2022, spinal cord stimulation accounted for the largest share in the neuromodulation industry for internal, by type.

On the basis of type, the internal neuromodulation market is segmented into spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electrical stimulation. The spinal cord stimulation accounted for the largest share of the market in 2022. The increasing number of people suffering from FBSS (failed back surgery syndrome), ischemia, and chronic pain will drive the market growth.

In 2022, transcutaneous electrical nerve stimulation accounted for the largest share in the external neuromodulation industry, by type.

The external neuromodulation market is segmented into transcutaneous electrical nerve stimulation, transcranial magnetic stimulation, and respiratory electrical stimulation. In 2022, transcutaneous electrical nerve stimulation dominated the largest share of the market. They are inexpensive, easily available to end users, and can be self-administered. Due to such benefits the growth of this segment will drive the market growth.

NORTH AMERICA Region Holds the Largest Share of the Neuromodulation Market.

The global neuromodulation market is segmented into four major regions: North America, Europe, the Asia Pacific, Rest of the World. North America dominated the market in 2022. Factors such as increasing incidences of neurological disorders, the highly developed healthcare system, and the large number of manufacturing companies are contributing to the large share of this regional segment.

Recent Developments of Neuromodulation Market industry

  • In 2023, Medtronic (Ireland) received CE (Conformité Européenne) Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS). In 2023, Boston Scientific Corporation (US) received the US FDA approval for the Vercise Neural Navigator 5 Software/ It is a part of the Vercise Genus Deep Brain Stimulation (DBS) Systems.
  • In 2023, Boston Scientific Corporation (US) entered into an agreement to acquire Relievant Medsystems, Inc. (US) to expand its neuromodulation portfolio to provide more treatment options for people living with chronic low back pain. In 2022, Medtronic (Ireland) received FDA approval for InterStim X System, which is a next-generation personalized sacral nerve stimulation therapy used for bladder and bowel control.

Key Market Players

KEY PLAYERS IN THE Neuromodulation Market INCLUDE

Want to explore hidden markets that can drive new revenue in Neuromodulation Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2023 $6.2 Billion
Projected Revenue by 2028 $11.0 Billion
Revenue Rate Poised to Grow at a CAGR of 12.0%
Market Driver Increasing focus on the development of advanced neuromodulation and neurostimulation technologies
Market Opportunity Large population and increasing healthcare expenditure in emerging countries

Key Questions Addressed by the Report

What is the projected market revenue value of the global Neuromodulation Market?
The global Neuromodulation market boasts a total revenue value of $11.0 Billion by 2028.
What is the estimated growth rate (CAGR) of the global Neuromodulation Market?
The global Neuromodulation market has an estimated compound annual growth rate (CAGR) of 12.0% and a revenue size in the region of $6.2 Billion in 2023.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Neuromodulation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
24
RESEARCH METHODOLOGY
28
EXECUTIVE SUMMARY
40
PREMIUM INSIGHTS
43
MARKET OVERVIEW
47
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising prevalence of neurological disorders and nerve injuries
    - Increasing focus on development of advanced neuromodulation and neurostimulation technologies
    - Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    - Growing geriatric population and subsequent increase in prevalence of neurological disorders
    - Availability of reimbursements for neuromodulation devices
    - Government-led support for research on neurological disorders
    RESTRAINTS
    - High cost of neuromodulation procedures
    - Preference for drug therapies over neuromodulation products
    - Adverse effects and complications associated with neuromodulation devices
    OPPORTUNITIES
    - Large population and increasing healthcare expenditure in emerging economies
    - Widening application scope of neuromodulation
    CHALLENGES
    - Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
    - Shortage of trained professionals
    - Product recalls
    TRENDS
    - Role of artificial intelligence (AI) in advancing neuromodulation
  • 5.3 VALUE CHAIN ANALYSIS
    RESEARCH AND DEVELOPMENT (R&D)
    MANUFACTURING AND ASSEMBLY
    DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    THREAT OF SUBSTITUTES
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.8 REGULATORY LANDSCAPE
    REGULATORY LANDSCAPE, BY REGION
    - North America
    - Europe
    - Asia Pacific
    - Japan
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.11 PRICING ANALYSIS
  • 5.12 TRADE ANALYSIS
  • 5.13 ECOSYSTEM MAPPING
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
NEUROMODULATION MARKET, BY TYPE
68
  • 6.1 INTRODUCTION
  • 6.2 INTERNAL NEUROMODULATION
    SPINAL CORD STIMULATION
    - Growing incidence of spinal cord injuries to fuel market growth
    DEEP BRAIN STIMULATION
    - Growing use to control debilitating symptoms caused by neurological disorders to drive market
    VAGUS NERVE STIMULATION
    - Rising geriatric population and high incidence of epilepsy to drive market
    SACRAL NERVE STIMULATION
    - Widening application scope of sacral nerve stimulation to drive market
    GASTRIC ELECTRICAL STIMULATION
    - Growing number of people suffering from severe gastroesophageal reflux disease (GERD) and gastroparesis to fuel market growth
  • 6.3 EXTERNAL NEUROMODULATION
    TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
    - Extensive use in healthcare sector, low cost, and ease of use to fuel market growth
    TRANSCRANIAL MAGNETIC STIMULATION (TMS)
    - Minimal patient discomfort associated with transcranial magnetic stimulation (TMS) to support demand
    RESPIRATORY ELECTRICAL STIMULATION
    - High treatment efficacy to fuel market growth
NEUROMODULATION MARKET, BY APPLICATION
83
  • 7.1 INTRODUCTION
  • 7.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION
    CHRONIC PAIN
    - High incidence of chronic pain to support market growth
    FAILED BACK SURGERY SYNDROME (FBSS)
    - Increasing incidence of failed back surgery syndrome (FBSS) with rising number of surgeries annually to drive demand
    ISCHEMIA
    - High effectiveness of neuromodulation for ischemia treatment to support market growth
  • 7.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION
    PARKINSON’S DISEASE
    - Rising incidence of Parkinson’s disease and growing R&D for innovation to drive market
    TREMORS
    - High efficacy of deep brain stimulation (DBS) in treating tremors to boost demand
    DEPRESSION
    - Rising research and clinical studies related to depression treatment to drive market
    OTHER DBS APPLICATIONS
  • 7.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION
    URINE INCONTINENCE
    - High incidence of urine incontinence to create growth opportunities
    FECAL INCONTINENCE
    - Reduced symptom recurrence with use of SNS in fecal incontinence treatment to drive demand
  • 7.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION (VNS), BY APPLICATION
    EPILEPSY
    - Advantages associated with VNS in epilepsy treatment to propel market growth
    OTHER VNS APPLICATIONS
  • 7.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
    GASTROPARESIS
    - Reduced hospitalization time for patients affected by gastroparesis by GES treatment to drive market
    OBESITY
    - High prevalence of obesity and risks associated with gastric bypass to fuel demand
  • 7.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
    TREATMENT-RESISTANT DEPRESSION
    - Increasing prevalence of depression to boost market growth
    OTHER TENS APPLICATIONS
  • 7.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
    DEPRESSION
    - High effectiveness of TMS and increased acceptance among patients to drive market
    MIGRAINE
    - High prevalence of migraine to support market growth
  • 7.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
    SPINAL CORD INJURY
    - Rising incidence of spinal cord injuries to fuel demand
NEUROMODULATION MARKET, BY REGION
100
  • 8.1 INTRODUCTION
  • 8.2 NORTH AMERICA
    US
    - Large presence of prominent players to drive market
    CANADA
    - Rising healthcare expenditure and increasing prevalence of chronic diseases to drive demand
    NORTH AMERICAN NEUROMODULATION MARKET: RECESSION IMPACT
  • 8.3 EUROPE
    GERMANY
    - Increasing healthcare expenditure and presence of favorable reimbursement policies to drive market
    UK
    - Rising healthcare expenditure and high public- and private-sector investments to fuel market growth
    FRANCE
    - Availability of insurance and favorable healthcare reforms to drive market
    ITALY
    - Easy access to healthcare services to create lucrative opportunities for market
    SPAIN
    - Growing government-led initiatives related to healthcare to support market growth
    REST OF EUROPE
    EUROPEAN NEUROMODULATION MARKET: RECESSION IMPACT
  • 8.4 ASIA PACIFIC
    JAPAN
    - Increasing prevalence of neurological disorders to drive demand
    CHINA
    - Growing geriatric population to fuel demand
    INDIA
    - Improvements in healthcare infrastructure to contribute to market growth
    REST OF ASIA PACIFIC
    ASIA PACIFIC NEUROMODULATION MARKET: RECESSION IMPACT
  • 8.5 ROW
    LATIN AMERICA
    - Increasing cases of depressive and post-traumatic stress disorders to drive demand
    MIDDLE EAST & AFRICA
    - Improvements in healthcare infrastructure and growing awareness regarding neuromodulation to drive market
    GCC COUNTRIES
    ROW NEUROMODULATION MARKET: RECESSION IMPACT
COMPETITIVE LANDSCAPE
146
  • 9.1 OVERVIEW
  • 9.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 9.3 REVENUE SHARE ANALYSIS, 2020–2022
  • 9.4 MARKET SHARE ANALYSIS, 2022
  • 9.5 COMPANY EVALUATION MATRIX, 2022
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
  • 9.6 START-UPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES) EVALUATION MATRIX, 2022
    PROGRESSIVE COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    COMPETITIVE BENCHMARKING
  • 9.7 COMPETITIVE SCENARIOS AND TRENDS
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
157
  • 10.1 KEY PLAYERS
    MEDTRONIC PLC
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BOSTON SCIENTIFIC CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ABBOTT LABORATORIES
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    LIVANOVA PLC
    - Business overview
    - Products offered
    - Recent developments
    NEVRO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    NEUROSIGMA, INC.
    - Business overview
    - Products offered
    - Recent developments
    NEUROPACE, INC.
    - Business overview
    - Products offered
    - Recent developments
    SOTERIX MEDICAL INC.
    - Business overview
    - Products offered
    - Recent developments
    SYNAPSE BIOMEDICAL INC.
    - Business overview
    - Products offered
    ALEVA NEUROTHERAPEUTICS SA
    - Business overview
    - Products offered
    - Recent developments
    THERANICA BIO-ELECTRONICS LTD.
    - Business overview
    - Products offered
    - Recent developments
    NEURONETICS
    - Business overview
    - Products offered
    AXONICS
    - Business overview
    - Products offered
    - Recent developments
    BIOINDUCTION
    - Business overview
    - Products offered
    - Recent developments
  • 10.2 OTHER PLAYERS
    GIMER MEDICAL
    NALU MEDICAL INC.
    HELIUS MEDICAL TECHNOLOGIES
    MICROTRANSPONDER
    MAGSTIM
    ELECTROCORE, INC.
    RENISHAW PLC
    TVNS TECHNOLOGIES GMBH
    BIOWAVEGO USA
    BIOTRONIK
    SALUDA MEDICAL PTY LTD.
APPENDIX
195
  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES
  • TABLE 2 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS
  • TABLE 3 MAJOR PRODUCT RECALLS
  • TABLE 4 NEUROMODULATION MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY END USER
  • TABLE 6 LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION
  • TABLE 7 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
  • TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION
  • TABLE 9 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 10 NEUROMODULATION MARKET: LIST OF CONFERENCES AND EVENTS, 2024–2025
  • TABLE 11 PRICE RANGE OF NEUROMODULATION DEVICES AND PROCEDURES, 2022
  • TABLE 12 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 14 COMPANIES AND THEIR ROLES IN NEUROMODULATION ECOSYSTEM
  • TABLE 15 NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 16 INTERNAL: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 17 INTERNAL: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 18 SPINAL CORD STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 19 INTERNAL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 20 DEEP BRAIN STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 21 INTERNAL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 22 VAGUS NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 23 INTERNAL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 24 SACRAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 25 INTERNAL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 26 GASTRIC ELECTRICAL STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 27 INTERNAL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 28 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 29 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 30 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
  • TABLE 31 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 32 TRANSCRANIAL MAGNETIC STIMULATION DEVICE OFFERED BY MAJOR COMPANIES
  • TABLE 33 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 34 RESPIRATORY ELECTRICAL STIMULATION DEVICE OFFERED BY MAJOR COMPANIES
  • TABLE 35 EXTERNAL: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 36 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 37 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 38 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 39 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 40 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 41 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 42 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 43 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 44 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 45 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 46 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 47 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 48 NEUROMODULATION MARKET FOR VAGUS NERVE SIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 49 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 50 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 51 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 52 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 53 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 54 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 55 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 57 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 58 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 59 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 60 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 61 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 62 NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 63 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 64 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 66 NORTH AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 67 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 68 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 69 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 70 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 72 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 73 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 74 US FDA-APPROVED PRODUCTS, 2019–2022
  • TABLE 75 US: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 76 US: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 77 US: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 78 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA, 2016–2031
  • TABLE 79 CANADA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 80 CANADA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 81 CANADA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 82 PREVALENCE OF DEMENTIA, BY COUNTRY, 2018 & 2050
  • TABLE 83 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 84 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 85 EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 86 EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 87 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 88 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 89 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 90 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 91 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 92 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 93 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 94 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 95 GERMANY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 96 GERMANY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 97 UK: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 98 UK: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 99 UK: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 100 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 101 FRANCE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 102 FRANCE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 103 ITALY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 104 ITALY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 105 ITALY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 106 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 107 SPAIN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 108 SPAIN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 109 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 110 REST OF EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 111 REST OF EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 118 SIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 123 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 124 JAPAN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 125 JAPAN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 126 CHINA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 127 CHINA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 128 CHINA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 129 INDIA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 130 INDIA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 131 INDIA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 132 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 133 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 134 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 135 ROW: NEUROMODULATION MARKET, BY COUNTRY/REGION, 2021–2028 (USD MILLION)
  • TABLE 136 ROW: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 137 ROW: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 138 ROW: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 139 ROW: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 140 ROW: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 141 ROW: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 142 ROW: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 143 ROW: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 144 ROW: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 145 ROW: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
  • TABLE 146 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 147 LATIN AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 148 LATIN AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 149 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 150 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 151 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 152 GCC COUNTRIES: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 153 GCC COUNTRIES: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 154 GCC COUNTRIES: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 155 NEUROMODULATION MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • TABLE 156 NEUROMODULATION MARKET: DEGREE OF COMPETITION
  • TABLE 157 OVERALL COMPANY FOOTPRINT
  • TABLE 158 COMPANY REGION FOOTPRINT
  • TABLE 159 COMPANY TYPE FOOTPRINT
  • TABLE 160 NEUROMODULATION MARKET: LIST OF KEY START-UPS/SMES
  • TABLE 161 NEUROMODULATION MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023
  • TABLE 162 NEUROMODULATION MARKET: DEALS, 2020–2023
  • TABLE 163 MEDTRONIC PLC: COMPANY OVERVIEW
  • TABLE 164 MEDTRONIC PLC: PRODUCT APPROVALS
  • TABLE 165 MEDTRONIC PLC: DEALS
  • TABLE 166 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 167 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 168 BOSTON SCIENTIFIC CORPORATION: DEALS
  • TABLE 169 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 170 ABBOTT LABORATORIES: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 171 LIVANOVA PLC: COMPANY OVERVIEW
  • TABLE 172 LIVANOVA PLC: PRODUCT APPROVALS
  • TABLE 173 LIVANOVA PLC: DEALS
  • TABLE 174 NEVRO CORPORATION: COMPANY OVERVIEW
  • TABLE 175 NEVRO CORPORATION: PRODUCT APPROVALS
  • TABLE 176 NEVRO CORPORATION: DEALS
  • TABLE 177 NEUROSIGMA, INC.: COMPANY OVERVIEW
  • TABLE 178 NEUROSIGMA, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 179 NEUROSIGMA, INC.: DEALS
  • TABLE 180 NEUROSIGMA, INC.: OTHERS
  • TABLE 181 NEUROPACE, INC.: COMPANY OVERVIEW
  • TABLE 182 NEUROPACE, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 183 NEUROPACE, INC.: OTHERS
  • TABLE 184 SOTERIX MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 185 NEUROPACE, INC.: OTHERS
  • TABLE 186 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW
  • TABLE 187 ALEVA NEUROTHERAPEUTICS SA: COMPANY OVERVIEW
  • TABLE 188 ALEVA NEUROTHERAPEUTICS SA: PRODUCT APPROVALS
  • TABLE 189 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW
  • TABLE 190 THERANICA BIO-ELECTRONICS LTD.: PRODUCT APPROVALS
  • TABLE 191 NEURONETICS: COMPANY OVERVIEW
  • TABLE 192 AXONICS: COMPANY OVERVIEW
  • TABLE 193 AXONICS: PRODUCT APPROVALS
  • TABLE 194 AXONICS: DEALS
  • TABLE 195 BIOINDUCTION: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE)
  • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 DATA TRIANGULATION
  • FIGURE 8 NEUROMODULATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 9 NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 10 NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 11 NEUROMODULATION MARKET, BY REGION
  • FIGURE 12 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS
  • FIGURE 13 INTERNAL NEUROMODULATION SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN MARKET IN 2022
  • FIGURE 14 CHINA TO REGISTER HIGHEST CAGR IN NEUROMODULATION MARKET DURING FORECAST PERIOD
  • FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 16 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 17 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS
  • FIGURE 18 PUBLISHED RESEARCH PAPERS, 2013–2022
  • FIGURE 19 NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 20 DIRECT DISTRIBUTION—PREFERRED STRATEGY OF PROMINENT COMPANIES
  • FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 22 KEY BUYING CRITERIA BY END USER
  • FIGURE 23 NEUROMODULATION MARKET: ECOSYSTEM MAPPING
  • FIGURE 24 KEY PLAYERS IN NEUROMODULATION MARKET
  • FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 26 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 27 PROJECTED NUMBER OF PEOPLE WITH ALZHEIMER’S DEMENTIA IN US, 2020–2060 (MILLION)
  • FIGURE 28 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 29 NEUROMODULATION MARKET: REVENUE ANALYSIS OF FIVE KEY PLAYERS, 2020–2022
  • FIGURE 30 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX, 2022
  • FIGURE 31 NEUROMODULATION MARKET: START-UPS/SMES EVALUATION MATRIX, 2022
  • FIGURE 32 MEDTRONIC PLC: COMPANY SNAPSHOT
  • FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 35 LIVANOVA PLC: COMPANY SNAPSHOT
  • FIGURE 36 NEVRO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 37 NEUROPACE, INC.: COMPANY SNAPSHOT
  • FIGURE 38 NEURONETICS: COMPANY SNAPSHOT
  • FIGURE 39 AXONICS: COMPANY SNAPSHOT

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the neuromodulation market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the neuromodulation market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was collected after acquiring knowledge about the neuromodulation market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (including various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants:

Neuromodulation  Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Medtronic (Ireland)

Manager

Abbott Laboratories (US)

VP Sales

NeuroSigma (US)

Regional Sales Head

Boston Scientific (US)

Sales Director

Market Size Estimation

All major product manufacturers offering various neuromodulation were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value neuromodulation market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of neuromodulation product at the regional and country level
  • Relative adoption pattern of each product type among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Neuromodulation Market Size: Bottom Up Approach

Neuromodulation  Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Neuromodulation Market Size: Top-Down Approach

Neuromodulation  Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the neuromodulation industry.

Market Definition

Neuromodulation is the alteration of nerve activity through electrical stimulation or drug infusion. It is carried out to modulate or normalize nervous tissue function. Neuromodulation devices include small electrodes placed in the brain, spinal cord, or peripheral nerves and connected via leads to an implantable pulse generator placed under the skin to generate electrical stimulation in a precise pattern.

Key Stakeholders

  • Manufacturers and distributors of neuromodulation products
  • Pharmaceutical and Biotechnology Companies
  • R & D centers
  • Diagnostic laboratories
  • Hospitals and clinics
  • Academic institutes
  • Research institutes
  • Market research and consulting firms

Report Objectives

  • To define, describe, segment, and forecast the global neuromodulation market by type, sample, application, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, challenges, and trends)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall neuromodulation market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the neuromodulation market into specific countries/regions in the Rest of Europe, the Rest of Asia Pacific, and the Rest of the World.

Company Information

  • Detailed analysis and profiling of additional market players (up to 3)

Previous Versions of this Report

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

Report Code BT 3571
Published in Aug, 2022, By MarketsandMarkets™

Neuromodulation Market by Technology- Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application (Ischemia, Chronic Pain, Parkinson’s, Depression, Tremor, Epilepsy, Migraine) - Global Forecast to 2025

Report Code BT 3571
Published in Feb, 2020, By MarketsandMarkets™

Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020

Report Code BT 3571
Published in Jul, 2015, By MarketsandMarkets™

Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020

Report Code BT 3571
Published in Jan, 2011, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Neuromodulation Market

DMCA.com Protection Status